

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: April 19, 2004 (use as many sheets as necessary)				<b>Complete if Known</b>	
Sheet	1	of	1	Application Number	Unassigned <i>10/826,302</i>
				Filing Date	4/19/04
				First Named Inventor	Chun Li
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	077319-0406

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	A1	US005479055	A	Mongelli et al.	12/1995	
	A2	US005046565	A	Brem et al.	12/1998	
	A3	US006127355	A	Greenwald et al.	10/2000	
	A4	US006218367	B	Jacob	04/2001	
	A5	US006202107	B	Li et al.	07/2001	
	A6	5,473,059	A	Mongelli et al.	12/1995	
	A7	5,626,862		Brem et al.	05/1997	
	A8	5,730,968		Butterfield et al.	03/1998	
	A9	5,776,925		Young et al.	07/1998	
	A10	5,846,565	A	Brem et al. (II)	12/1998	
	A11	6,127,355	A	Greenwald et al.	10/2000	
	A12	6,218,367	B	Jacob	04/2001	
	A13	6,262,107	B	Li et al.	07/2001	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office <sup>3</sup>	Number <sup>4</sup>			
						T <sup>6</sup>

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		Author	Title	Item	Date
	A14	Li et al.	"Enhancement of Tumor Radioreponse of A Murine Ovarian Carcinoma By Poly(L-Glutamic Acid)-Paclitaxel Conjugate", CTI 9 <sup>th</sup> Annual International Symposium on Recent Advances in Drug Delivery Systems, February 22-25, 1999, (2 pages).		
	A15	Ke et al.	"Schedule-Independent Radiosensitization of a Murine Ovarian Oca-1 Tumor by PG-TXL", CTI Proceedings of the American Association for Cancer Research, Vol 40, # 4223, Ref. 248, March 1999 (1 page).		
	A16	Li et al.	"Water-Soluble Polyglutamic Acid-Paclitaxel Conjugate (PGA-Paclitaxel): Antiumour Regression in Rats Braeing 13762 Mammary Carcinoma", Pharmaceutical Research, September 1996, Vol. 13, Number 9, page S-368, Abstract PDD 7541, see entire abstract.		

Examiner Signature	<i>CM</i>	Date Considered	9-27-04
--------------------	-----------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.